Endometrial Cancer Trial, Recruiting

Written by an AI model from the ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• Women aged 18 or older at the time of signing the consent form
• People with a confirmed diagnosis of cervical cancer (specifically squamous cell carcinoma, adenocarcinoma, or adenosquamous carcinoma, confirmed through tissue testing)
• People whose cervical cancer is classified as Stage IIB to IVA using the 2018 FIGO staging system
• People whose cancer has at least one measurable tumour area, as defined by standard imaging guidelines (RECIST version 1.1)
• People whose case has been reviewed by the carbon ion radiotherapy specialist team and deemed appropriate for that treatment
• People who are willing to receive carbon ion radiotherapy at Zhejiang Cancer Hospital and cover all related treatment costs themselves
• People with complete medical and imaging records available
• People willing to take part in the trial and complete questionnaire surveys
• People willing to provide biological samples, including cervical tissue, various body fluid samples, and other tissue samples
• People willing to attend regular, scheduled follow-up appointments at the trial hospital
• People with a general health and activity level rated 0–2 on the ECOG scale (meaning fully active to capable of limited self-care) (confirm with trial site)
• People who have not previously had surgery, radiotherapy, or chemotherapy for cervical cancer
• People whose blood, liver, and kidney test results fall within acceptable ranges in the week before treatment begins (confirm with trial site for specific values)
• People whose life expectancy is estimated to be at least 6 months

Who may not be able to join:

• People with serious ongoing health conditions that are not well controlled, such as heart disease, high blood pressure, diabetes, persistent infection, active stomach ulcers, or uncontrolled mental health conditions
• People who currently have a second, separate active cancer
• People whose cancer has spread into the rectum (Stage IVA involvement) or into the lining of the abdomen (peritoneal metastasis)
• People who have previously received immunotherapy treatments, including medications that target PD-1, PD-L1, or CTLA-4
• People who have previously had major surgery, radiotherapy, or systemic treatment for cervical cancer (note: a minor cervical procedure called conisation is permitted)
• People who have taken any experimental drug within the 4 weeks before immunotherapy is due to start
• People with a confirmed immune system deficiency, or those who have been taking high-dose steroid medications or other immune-suppressing drugs in the 7 days before immunotherapy begins
• People who have previously had a severe allergic reaction (grade 3 or higher) to an immunotherapy drug
• People who have had an active autoimmune disease requiring systemic treatment within the past 2 years (routine hormone replacement therapies such as thyroid medication, insulin, or low-dose steroids are not excluded)
• People with a history of lung inflammation (pneumonitis) or scarring lung disease (interstitial lung disease) that previously required steroid treatment, or who currently have active lung inflammation or scarring
• People with an active infection that currently requires treatment with medication
• People with active hepatitis B or active hepatitis C infection
• People with any other condition, treatment, or test result that the trial investigators believe could interfere with the study results or create additional risks
• People with a known psychiatric illness or substance use issue that may affect their ability to follow the study requirements; women who are pregnant, breastfeeding, or planning to become pregnant during the study period (from screening through to 120 days after the last study treatment)
• People who have previously received a transplant of donated tissue or a solid organ
• People with a known HIV infection
• People who have metal implants located in the path of the radiation beam that may affect the accuracy of radiotherapy dose planning
• People who request to withdraw from the study

Important: Always verify eligibility with the trial site directly before applying.